药物诱导的炎症:文学综述
1Faculty of Data Science, Musashino University, 3-3-3 Ariake Koto-ku, Tokyo, 135-8181, Japan.
Chemico-biological interactions
|October 19, 2024
概括
药物可以引起全身炎症,影响各种器官. 了解药物诱导的炎症类型,症状和治疗方法,以及预防措施,是医生和患者有效管理这种风险的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 毒理学 毒理学 毒理学
背景情况:
- 药物,从NSAID到化疗,可以诱导全身炎症.
- 药物诱导的炎症呈现出多种症状,可以通过免疫反应来分类.
- 准确的诊断和风险评估因新疗法而复杂化.
研究的目的:
- 审查药物诱导炎症的原因,机制和类型.
- 探索诊断方法和当前/新兴的治疗策略.
- 为医疗保健提供者和患者强调预防措施.
主要方法:
- 关于药物诱导炎症的综合文献综述.
- 对已知引起炎症反应的药物类别的分析.
- 检查诊断标准和治疗干预措施.
主要成果:
- 确定NSAID和化疗是常见的罪祸首.
- 描述了药物诱导炎症的四个基于免疫的类别.
- 突出发烧,不适,关节疼痛,皮疹和胀作为常见症状.
- 在生物标志物和药物诱导肝损伤的遗传风险评估方面取得了显著进展.
结论:
- 药物诱导的炎症需要仔细监测和管理.
- 医生与患者的合作对于预防和治疗至关重要.
- 对生物标志物和治疗方法的持续研究提高了诊断准确性和风险评估.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117


